Application of lauromacrogol in preparation of medicine for treating nasal polyp

Abstract

The invention discloses application of lauromacrogol in preparation of a medicine for treating nasal polyp, and belongs to the technical field of medicines. The invention discloses an application of lauromacrogol in preparation of a medicine for treating nasal polyp. When lauromacrogol is used for treating nasal polyp, the nasal polyp can be reduced, and clinical symptoms can be eliminated. According to clinical data statistics, the lauromacrogol is adopted to treat nasal polyp, the cure rate is 89.56%, the improvement rate is 10.44%, and no recurrent symptoms occur. The invention creatively provides a new application of lauromacrogol, and the lauromacrogol is used for preparing the medicine for treating nasal polyp, and is definite in effect, small in adverse reaction and worthy of popularization and application.

Description

Technical Field

[0001] The invention belongs to the technical field of medicines, and particularly relates to application of lauromacrogol in preparing medicines for treating nasal polyps. Background Art

[0002] Nasal polyps are benign lesions formed in the nasal cavity, which are essentially extremely edematous inflammatory tissues. Nasal polyps are mainly composed of highly edematous nasal mucosa, which contains a large number of eosinophils, plasma cells and lymphocytes, accompanied by the release of a large number of inflammatory mediators. Its surface is smooth, pink or grayish white, translucent, shaped like lychee flesh, soft to the touch and movable. The formation of nasal polyps is a complex multifactorial process involving multiple factors such as allergic reactions, chronic inflammation, genetic factors, aspirin intolerance, nasal ciliary dyskinesia, and the middle nasal meatus microenvironment.

[0003] In the treatment of nasal polyps, glucocorticoid drugs such as fluticasone propionate nasal spray are commonly used local treatment methods. These drugs achieve therapeutic effects by reducing inflammatory cell infiltration in nasal polyp tissue, downregulating cytokine levels, and inhibiting the release of vasoactive neurotransmitters. Early small polyps can be significantly reduced or even disappear completely under the action of hormones; however, when nasal polyps are significantly enlarged, surgical treatment is required. Although surgical treatment of nasal polyps can effectively remove polyps, it also has its disadvantages and potential risks. Surgical treatment is not recommended for those who are in poor physical condition and cannot tolerate surgery.

[0004] Therefore, providing a drug for treating nasal polyps, which can effectively treat nasal polyps, avoid surgical risks, and has little adverse reactions, has become an urgent problem to be solved by technical personnel in this field. Summary of the invention

[0005] The purpose of the present invention is to provide an application of lauromacrogol in preparing a medicine for treating nasal polyps, which can shrink nasal polyps and eliminate clinical symptoms, and has little adverse reaction.

[0006] To achieve the above purpose, the technical solution adopted by the present invention is as follows:

[0007] The invention discloses an application of lauromacrogol in preparing a medicine for treating nasal polyps.

[0008] In some embodiments of the present invention, the drug is an injection.

[0009] In some embodiments of the present invention, the content of lauromacrogol in the injection is 8-12 mg / ml.

[0010] In some embodiments of the present invention, the content of lauromacrogol in the injection is 10 mg / ml.

[0011] In some embodiments of the present invention, the drug is injected into the mucosal tissue of the nasal polyp.

[0012] In some embodiments of the present invention, the drug is used for small nasal polyps that cannot be directly removed surgically or nasal polyps with special locations or multiple recurrences.

[0013] In some embodiments of the present invention, the drug is used for people with poor physical condition who cannot tolerate surgery.

[0014] Lauromacrogol belongs to the class of polyoxyethylene lauryl alcohol ether compounds and is currently approved for emergency hemostasis of esophageal varicose bleeding under endoscopy and sclerotherapy of varicose veins. Lauromacrogol is a sclerosing agent. After being injected near varicose veins, lauromacrogol can cause fibrosis around varicose veins, compress varicose veins, and achieve the purpose of hemostasis; after intravenous injection of lauromacrogol, it can damage the vascular endothelium, promote thrombosis, and block blood vessels, thereby playing a hemostatic role.

[0015] The present invention creatively utilizes lauromacrogol to treat nasal polyps by injecting it into the mucosal tissue of nasal polyps. After lauromacrogol is injected into the mucosal tissue, it can directly damage vascular endothelial cells, causing them to be rapidly destroyed and promoting the formation of thrombus. After the vascular endothelial cells are damaged, a series of physiological reactions will be triggered, including the aggregation and deposition of fibrin, platelets and red blood cells, and finally thrombus will be formed at the injection site.

[0016] As thrombus formation occurs, a sterile inflammatory response will occur at the injection site, further leading to tissue fibrosis. This fibrosis process will permanently occlude pathological blood vessels, thereby achieving the purpose of hardening. The formation of fibrosis can also re-fix the loose mucosal tissue to the muscle wall to prevent it from shifting or falling out again.

[0017] In summary, after the injection of lauromacrogol, the endothelial cells in the nasal polyp tissue are destroyed, coagulated and denatured, and the blood vessels are embolized, and then the tissue produces aseptic coagulation and tissue atrophy. Lauromacrogol can not only promote thrombosis at the injection site, but also activate the coagulation mechanism, causing the vascular cavity at the injection site to be occluded, thereby achieving the effect of hemostasis.

[0018] Through its dual effects of hardening and hemostasis, lauromacrogol injection can significantly reduce the risk of bleeding at the injection site and improve the safety of treatment.

[0019] The method of using lauromacrogol injection to treat nasal polyps is as follows:

[0020] Step 1: Use nasal endoscopy, imaging examination, coagulation function test and other methods to determine the size, location and number of nasal polyps, and evaluate various basic functional indicators of the body.

[0021] Step 2: Observe the diseased tissue under the guidance of a nasal endoscope and inject the sclerosant at multiple points on the nasal polyps. Stop the injection when the polyp mucosa becomes grayish white.

[0022] Step 3: After the injection, the patient needs to be observed for a period of time, generally 15 to 30 minutes, so that the doctor can detect and deal with possible complications in time.

[0023] Compared with the prior art, the present invention has the following beneficial effects:

[0024] The invention utilizes lauromacrogol to treat nasal polyps, which can reduce the size of nasal polyps and eliminate clinical symptoms, and has a precise effect and good safety. The invention utilizes lauromacrogol to treat nasal polyps, which can avoid the trauma caused by surgery and a series of complications after surgery, and can be comparable to surgery in improving the symptoms, or even better.

[0025] The use of lauromacrogol to treat nasal polyps has the advantages of being low-cost, non-invasive, rapid recovery, and no need for hospitalization, making it more acceptable to patients.

[0026] Compared with traditional surgical treatment, the use of lauromacrogol to treat nasal polyps is simpler and generally less prone to bleeding. Its advantages of minimal invasiveness, repeatability, accurate positioning, high efficacy, rapid effect, and few complications have brought broad development prospects for the clinical treatment of nasal polyps. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Attached Figure 1 This is a schematic diagram of the operation of using lauromacrogol to treat nasal polyps according to the present invention;

[0028] Attached Figure 2 Schematic diagram of the disease course of nasal polyps treated with lauromacrogol. DETAILED DESCRIPTION

[0029] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.

[0030] The specification of lauromacrogol injection used in this experiment is 10ml:100mg / vial, produced by Shaanxi Tianyu Pharmaceutical Co., Ltd.

[0031] 1 Case inclusion criteria

[0032] 1.1 Indications

[0033] (1) Suitable for small, specially located, or repeatedly recurrent nasal polyps that cannot be directly removed surgically;

[0034] (2) Patients with poor physical condition who cannot tolerate surgery.

[0035] 1.2 Contraindications

[0036] (1) It is contraindicated for patients who are allergic to alcohol (lauromacrogol).

[0037] (2) Use with caution in patients with severe cardiovascular and cerebrovascular diseases, liver and kidney dysfunction, or other systemic diseases.

[0038] 2 Treatment Process

[0039] 2.1 Preoperative preparation

[0040] (1) Detailed medical history before surgery, including duration of illness, treatment history and type of treatment (conservative or surgical), treatment effect, and current clinical symptoms;

[0041] (2) Preoperative examinations include nasal endoscopy, imaging examinations, coagulation function tests, etc., to determine the size, location, and number of nasal polyps and various basic body function indicators;

[0042] (3) Preoperative endoscopic nasal examination to understand the location of inflammatory secretions in the nasal cavity (sinus ostium or nasal passage), the location, size and number of nasal polyps, and anatomical variations of the nasal cavity (adhesions, nasal septum deviation, hyperplasia or hypertrophy of the middle or inferior turbinate, etc.);

[0043] (4) Preoperative CT scan of the nasal cavity and paranasal sinuses (coronal and horizontal) The coronal position is: the head is in the prone position, the head is hyperextended, and the coronal fault line is perpendicular to the auditory canthus line. The horizontal position uses the auditory canthus line as the baseline. A bone window should be used, with a window width of 1000HZ, a window position of +90HU, a layer thickness of 2MM, and an average of 12-16 layers.

[0044] (5) Preoperative coagulation function test to understand blood coagulation function, check for potential coagulation problems, and prevent massive bleeding.

[0045] 2.2 Treatment process

[0046] Under the guidance of nasal endoscope, the lesion tissue is observed, and the sclerosant is injected at multiple points of the nasal polyps. 0.1ml-0.5ml of the stock solution is injected at each point (depending on the size of the lesion). The injection can be stopped when the polyp mucosa is grayish white. The total dose of a single treatment is less than 3ml of the stock solution. If supplementary treatment is required, repeated injections can be performed at intervals of one week until the nasal polyps are reduced and the patient's clinical symptoms are eliminated. After the injection, it is necessary to observe for a period of time so that the doctor can promptly detect and deal with possible complications.

[0047] 3. Postoperative precautions

[0048] (1) Postoperative care: Patients need to keep their nasal cavity clean and dry, avoid strenuous exercise and forceful nose blowing to prevent nasal bleeding and infection.

[0049] (2) Follow-up: Follow-up was conducted at 1 month, 3 months, and 6 months after surgery to observe the reduction of nasal polyps and the elimination of clinical symptoms of the patient.

[0050] 4. Efficacy evaluation criteria

[0051] Cure: Clinical symptoms disappeared, nasal endoscopy showed good sinus patency, epithelialization of the surgical cavity mucosa, and no purulent secretions.

[0052] Improvement: Symptoms improved, and nasal endoscopy showed edema, hypertrophy or granulation tissue formation in some areas of the surgical mucosa, with a small amount of purulent secretions.

[0053] Ineffective: No improvement in clinical symptoms; endoscopy revealed adhesions in the surgical cavity, stenosis or occlusion of the sinus opening, polyp formation, and purulent secretions.

[0054] 5 Treatment Results

[0055] After 6 months of follow-up, the cure rate was 89.56%, the improvement rate was 10.44%, and no recurrence occurred.

[0056] In summary, the use of lauromacrogol in the treatment of nasal polyps is effective with few adverse reactions and is worthy of promotion and application.

[0057] The above are preferred embodiments of the present invention and are not intended to limit the present invention. Within the spirit and principles of the present invention, technicians familiar with the field can make various corresponding changes and modifications based on the present invention, but these corresponding changes and modifications should all fall within the scope of protection of the claims attached to the present invention.

Claims

1. The application of lauromacrogol in the preparation of medicines for treating nasal polyps.

2. The use according to claim 1, characterized in that: The medicine is an injection.

3. The use according to claim 2, characterized in that: The content of lauromacrogol in the injection is 8-12 mg / ml.

4. The use according to claim 2, characterized in that: The content of lauromacrogol in the injection is 10 mg / ml.

5. The use according to any one of claims 2 to 4, characterized in that: The drug is injected into the mucosal tissue of the nasal polyp.

6. The use according to any one of claims 2 to 4, characterized in that: The drug is used for small nasal polyps that cannot be directly removed surgically or nasal polyps with special locations or multiple recurrences.

7. The use according to any one of claims 2 to 4, characterized in that: The medicine is used for people with poor physical condition who cannot tolerate surgery.

Images